This hosted session will explore the use of digital implanted telemetry in rodent models as an essential tool in investigative toxicology.
By offering reliable, real-time monitoring of physiological responses to toxicants, telemetry enables the early detection of adverse effects on key organ systems, thereby enhancing the translational accuracy of preclinical studies.
William Salvail (IPS Therapeutique Inc) will explore the advantages of digital implanted telemetry for assessing cardiac function, comparing it to traditional analog systems in the context of preclinical toxicology studies. His study evaluated the easyTEL analog and digital telemetry implants in mice, analyzing their performance under normal conditions and in response to proarrhythmic drugs, hypoxia, and handling stress.
Dr. Monica Metea (Preclinical Electrophysiology Consulting, LLC) will present advanced methods for streamlining telemetry electrophysiology analytics supported by the end-to-end computational platform LucerumKey. The talk will highlight drug development applications of automated neuroanalytics and statistics for translational pharmaco-EEG and qEEG-sleep across species (rodents, large animals, and human); options for integration of multivariate physiological data (e.g., connectomics, pharmaco-ECG, and more); and database scaling for bioinformatics research.
Attendees will gain insights into the practical methodologies, regulatory significance, and strategic applications of digital telemetry in toxicology.
William Salvail is a passionate, result-driven scientist with a keen interest for business development.
He obtained his bachelor’s degree from Bishop’s University studying physiology (Honours, Honorable Mention for Academic Excellence), and his Master’s degree shortly after from University of Sherbrooke, where he studied cardiovascular failure in septic shock, funded by a Fond de Recherche du Quebec scholarship.
He has now worked alongside the IPS Therapeutique team for 5 years, driving innovation in drug development by exploiting and refining the best disease models available to the scientific community. He specialized in projects involving the cardiovascular system, and has ovserseen all telemetry studies of the company in the past 2 years.
Dr. Monica Metea is the founder of Preclinical Electrophysiology Consulting, LLC, a leading provider of neuroscience-focused consulting, and Lucerum, Inc, a groundbreaking end-to-end computational software platform company. Together with a talented team of expert neuroscientists and data engineers, she has contributed to numerous preclinical and clinical trial projects introducing new drugs to the market, with focus on drug safety and neuroanalytic biomarkers. As research partners with pharmaceutical developers and clinical experts, her team has responded to the critical need for streamlined tools that harness the biomarker power of electrophysiology to gain insights into brain function, predict drug or treatment response, and guide therapies.
Dr. Metea’s credentials include a doctorate in neuroscience focusing on electrophysiology and related postdoctoral studies. Prior to becoming a scientist entrepreneur, she held strategic, operational leadership and senior scientific roles in Contract Research Organizations providing support to the pharmaceutical industry.
By browsing this website, you accept the use of cookies for statistical purposes.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
